Title of article
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Author/Authors
Luc F Van Gaal and for the STORM Study Group، نويسنده , , Aila M Rissanen، نويسنده , , André J. Scheen، نويسنده , , Olivier Ziegler، نويسنده , , Stephan Rossner ، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2005
Pages
9
From page
1389
To page
1397
Abstract
Background
In animal models, cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidaemia. We assessed the effect of rimonabant, a selective CB1 blocker, on bodyweight and cardiovasc
Journal title
The Lancet
Serial Year
2005
Journal title
The Lancet
Record number
587974
Link To Document